c-Fms
CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R
c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.
c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).
All Product Categories
-
c-Fms Related Products (147)
Related Products (147)
-
Recombinant Proteins (24)
-
Antibodies (8)
-
c-Fms-IN-2
0 Imagesc-Fms-IN-2 is a FMS kinase inhibitor with an IC50 of 0.024 μM.
-
Pazopanib-13C,d3 hydrochloride
0 ImagesCat. No.: HY-12009SCAS No.: 1261398-44-0Synonyms: GW786034-13C,d3 hydrochloride
-
GENZ-882706
0 ImagesCat. No.: HY-101526CAS No.: 2070864-35-4Synonyms: RA03546849GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
-
c-Fms-IN-3
0 Imagesc-Fms-IN-3 is an orally active c-Fms (CSF1R) kinase inhibitor (IC50 = 0. 8 nM). c-Fms-IN-3 inhibits CSF1R kinase activity and reduces macrophage populations. c-Fms-IN-3 reduces bone erosion, pannus invasion, cartilage damage, and inflammation in collagen (HY-NP003)-induced arthritis mouse model. c-Fms-IN-3 is useful for arthritis research.
-
BPR1R024 mesylate
0 ImagesCat. No.: HY-132935ACAS No.: 2763365-40-6BPR1R024 mesylate is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 mesylate is the equivalent of BPR1R024 (HY-132935). BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology.
-
c-Fms-IN-13
0 Imagesc-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor with an IC50 value of 17 nM. c-Fms-IN-13 can be used as an anti-inflammatory agent.
-
GW2580-d6
0 ImagesGW2580-d6 is the deuterium labeled GW2580. GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling.
-
BRD4-BD1/2-IN-3
0 ImagesBRD4-BD1/2-IN-3 (Compound B6) is a selective BRD4 BD2 inhibitor with an IC50 of 0.41 nM for BRD4 BD2 over BRD4 BD1. BRD4-BD1/2-IN-3 significantly inhibits the LPS (HY-D1056)-induced expression of IL-6. BRD4-BD1/2-IN-3 shows anti-inflammatory activities by modulating the TNF and NF-κB signaling pathway. BRD4-BD1/2-IN-3 can be used for inflammatory diseases research.
-
JNJ-28312141
0 ImagesCat. No.: HY-13496CAS No.: 885692-52-4JNJ-28312141 is an inhibitor for colony-stimulating factor-1 receptor (CSF-1R or FMS), with an IC50 of 0.69 nM. JNJ-28312141 inhibits proliferation of BDBM, MV-4-11, M-o7e, TF-1 with an IC50s of 2.6, 21, 41 and 150 nM, respectively. JNJ-28312141 exhibits anti-inflammatory activity in mouse arthritis model.
-
Segigratinib
0 ImagesCat. No.: HY-159503CAS No.: 1882873-93-9Synonyms: 3D185 free base; HH185 free baseSegigratinib is a fibroblast growth factor receptor tyrosine kinase inhibitor, with antineoplastic effect.
-
PLX3397 in AIN-76A Diet (600 ppm)
0 ImagesCat. No.: HY-AF16749XPLX3397 in AIN-76A Diet (600 ppm) is a feed containing Pexidartinib (PLX3397) (HY-16749), with AIN-76A as the base feed at a concentration of 600 ppm. PLX3397 in AIN-76A Diet (600 ppm) can be used to study the effects of Pexidartinib (PLX3397) on animal organisms. PLX3397 in AIN-76A Diet (600 ppm) does not include a control group feed and is recommended for use with the control group AIN-76A (HY-AF0001).
-
JMC14
0 ImagesCat. No.: HY-174366CAS No.: 2256080-83-6JMC14 is a selective and orally active PI3Kδ and CSF1R inhibitor with IC50 values of 12 nM and 143 nM, respectively. JMC14 preferentially inhibits PI3Kδ-mediated signaling at the cellular level. JMC14 demonstrates potent antitumor activity against B-cell lymphomas and triple-negative breast cancer (TNBC) in both in vitro and vivo studies. JMC14 can be used for the study of antitumor immunity.
-
Sotuletinib dihydrochloride
0 ImagesCat. No.: HY-12768BCAS No.: 2222138-40-9Synonyms: BLZ945 dihydrochlorideSotuletinib (BLZ945) dihydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib dihydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research.
-
Axl/Mer/CSF1R-IN-2
0 ImagesCat. No.: HY-153277CAS No.: 2394874-63-4
-
IACS-9439
0 ImagesCat. No.: HY-153243CAS No.: 2231259-36-0IACS-9439 is a potent, selective, and orally active CSF1R inhibitor with a Ki value of 1 nM inhibitor. IACS-9439 can be used for advanced solid tumors research.
-
ABD-295
0 ImagesCat. No.: HY-111248CAS No.: 871113-99-4ABD-295, a biphenylsulfide derivative, is an antiresorptive agent, osteoclast inhibitor. ABD-295 has potent inhibitory effects on osteoclastic bone resorption in vitro. ABD-295 prevents ovariectomy-induced bone loss in vivo[1].
-
CSF1R-IN-5
0 ImagesCat. No.: HY-144041CAS No.: 2716184-93-7CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11).
-
CSF1R-IN-7
0 ImagesCat. No.: HY-147608CAS No.: 2738328-56-6CSF1R-IN-7 (Formula I) is a CSF-1R inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research.
-
CSF1R-IN-9
0 ImagesCat. No.: HY-147610CAS No.: 2765301-84-4CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor with an IC50 of 0.028 μM.
